Status:
TERMINATED
Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
Lead Sponsor:
HKGepitherapeutics
Collaborating Sponsors:
Kazakh Research Institute of Oncology & Radiology
Montreal EpiTerapia Inc.
Conditions:
Breast Cancer
Breast Cancer Female
Eligibility:
FEMALE
18-90 years
Brief Summary
A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive ...
Eligibility Criteria
Inclusion
- Histological confirmed breast cancer subtypes (DCIS and invasive)
Exclusion
- Pregnant women
- Minors (subjects less than 18 years of age)
- Prisoners
- Patients with known infectious disease, such as human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B, C
- Patients having other than one cancer
- Subjects unable to consent for themselves
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT03480659
Start Date
June 1 2018
End Date
September 1 2021
Last Update
December 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kazakh Institute of Oncology and Radiology
Almaty, Kazakhstan